a1 Respiratory Medicine Department, Prince Philip Hospital, Bryngwynmawr, Dafan, Llanelli, United Kingdom
a2 Oncology Department, Glan Clwyd Hospital, Rhyl, Denbighshire, United Kingdom
Introduction: Surgery is the treatment of choice in stage I and II non-small-cell lung cancer (NSCLC). In the management of patients who are medically unfit to tolerate surgical intervention or who refuse surgery, radiotherapy is an acceptable alternative. We have performed a retrospective analysis of the effectiveness of radical radiotherapy in patients with early stage NSCLC treated over a period of 4 years.
Methods: Thirty nine patients treated with radiotherapy of radical intent were identified. All patients received hypofractionated radiotherapy with a total dose of 55Gy in 20 fractions.
Results: The median survival of all cases was 29 months. The one and two-year survival was respectively 61 % and 41%. The median survival of patients ≥75 years was 28 months, and age was the only prognostic factor identified in this analysis that affected survival.
Conclusions: The presented survival results are consistent with those from other series published in the literature. At present, radical radiotherapy is often offered to patients with medically inoperable stage I and II NSCLC or those who decline surgery. But there is emerging evidence that some new techniques like stereotactic radiotherapy could be also used in the operable, early stage NSCLC.
(Received October 05 2011)
(Revised December 01 2011)
(Accepted December 10 2011)
c1 Correspondence to: Maria Wilczynska, Respiratory Medicine Department, Prince Philip Hospital, Bryngwynmawr, Dafan, Llanelli, United Kingdom. Tel: +44 (0)1554 756567. E-mail: firstname.lastname@example.org